Afore Capital

Pre-seed as a discipline is older than most people remember, but Afore Capital was among the first firms to treat it as an institutional product rather than as a stepping stone toward seed. The San Francisco firm has built roughly five hundred million dollars in assets under management around the proposition that the riskiest part of a venture-backed company’s life can be priced, diligenced, and supported with the same rigor that a Series A investor brings to a later-stage company. Healthcare exposure has come opportunistically rather than thematically, with bets including Modern Health and BenchSci that demonstrate the firm’s willingness to back ambitious founders attacking real markets at the moment when most institutional capital still considers them too early.

The thesis at Afore is stage-defined rather than sector-defined. The firm invests at pre-seed across software, marketplaces, fintech, healthcare, and consumer, with the unifying argument that pre-seed deserves a specialist rather than a generalist tourist. The firm’s published positioning emphasizes that pre-seed companies require different diligence, different milestones, and different post-investment support than seed-stage companies, and Afore has built the team and the operational practices around that view. Healthcare exposure within the portfolio sits in digital health and mental and behavioral health, areas where the founder-led commercial wedge is more important than the underlying clinical infrastructure. The firm does not typically back deeply regulated medical device or biotech companies at pre-seed; it prefers software-enabled healthcare businesses where the early commercial signal can be built without a multi-year regulatory path.

The portfolio includes Modern Health, the workplace mental health platform that scaled into one of the larger employer-purchased mental health benefits during the early 2020s, and BenchSci, the Toronto-based life sciences software company applying machine learning to preclinical research workflows. Both companies illustrate the firm’s pre-seed pattern: substantial market opportunity, capable founders, and product wedges that could be validated with modest early capital. The firm’s broader portfolio extends well beyond healthcare, which means founders engaging Afore should treat the firm as a generalist pre-seed specialist rather than as a healthcare-dedicated investor.

Check sizes fall in the one-to-five million dollar range, large by historical pre-seed standards and reflective of the firm’s view that real pre-seed companies require enough capital to reach a meaningful milestone before raising again. Afore leads pre-seed rounds, prices them, and takes board seats. Reserves are managed actively for follow-on into seed and Series A rounds where the firm’s portfolio companies have hit their milestones. Founders raising sub-million-dollar rounds will find Afore too institutional; founders raising priced seed rounds with established metrics will find it too early.

Decision-making sits with the partner team in San Francisco. The firm runs a structured diligence process that is fast by venture standards but rigorous by pre-seed standards. Founders should expect multiple partner conversations within a compressed window once the firm is engaged, and should expect a clear yes or no on a defined timeline rather than a slow drift into ambiguity.

The most effective approach is a warm introduction from a founder Afore has backed, supplemented by a clear and concise pitch document. The firm responds well to founders who can articulate the pre-seed milestone they are buying with the round and who have specific commercial hypotheses to test. Pitches that emphasize narrative over metrics are received politely but rarely advance.

Founders should know that Afore is a pre-seed shop in the institutional sense: priced rounds, board seats, and active engagement. The firm is helpful on company-building basics, including hiring, pricing, and early go-to-market structure. It is less helpful on healthcare-specific clinical and regulatory questions, and founders building heavily regulated digital health products should plan to bring in a healthcare specialist alongside Afore as the company matures.